BridgeBio Pharma, Inc. (BBIO)
74.29
+0.02
(+0.03%)
USD |
NASDAQ |
Nov 06, 16:00
74.40
+0.11
(+0.15%)
After-Hours: 20:00
BridgeBio Pharma Cash from Investing (Quarterly) : 36.61M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 36.61M |
| June 30, 2026 | 17.89M |
| March 31, 2026 | -42.74M |
| December 31, 2025 | -13.75M |
| September 30, 2025 | 4.464M |
| June 30, 2025 | -11.45M |
| March 31, 2025 | -1.595M |
| December 31, 2024 | -3.237M |
| September 30, 2024 | 38.23M |
| June 30, 2024 | 3.039M |
| March 31, 2024 | 22.75M |
| December 31, 2023 | -0.066M |
| September 30, 2023 | 37.68M |
| June 30, 2023 | 4.119M |
| March 31, 2023 | 12.30M |
| December 31, 2022 | 17.96M |
| September 30, 2022 | 146.86M |
| June 30, 2022 | 149.70M |
| Date | Value |
|---|---|
| March 31, 2022 | 138.62M |
| December 31, 2021 | 21.80M |
| September 30, 2021 | 62.15M |
| June 30, 2021 | -84.31M |
| March 31, 2021 | -282.05M |
| December 31, 2020 | 78.02M |
| September 30, 2020 | -44.05M |
| June 30, 2020 | -128.98M |
| March 31, 2020 | 63.12M |
| December 31, 2019 | 22.18M |
| September 30, 2019 | -1.171M |
| June 30, 2019 | -29.21M |
| March 31, 2019 | -2.427M |
| December 31, 2018 | -47.80M |
| September 30, 2018 | -0.588M |
| June 30, 2018 | 44.57M |
| March 31, 2018 | -2.985M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Ionis Pharmaceuticals, Inc. | 23.50M |
| Pfizer Inc. | -2.026B |
| Cytokinetics, Inc. | 67.93M |
| Vertex Pharmaceuticals, Inc. | -6.101B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.17M |
| Cash from Financing (Quarterly) | 863.01M |
| Free Cash Flow | -369.80M |
| Free Cash Flow Per Share (Quarterly) | -0.2268 |
| Free Cash Flow to Equity (Quarterly) | -56.22M |
| Free Cash Flow to Firm (Quarterly) | 12.23M |
| Free Cash Flow Yield | -2.55% |